Skip to main content
OpenTrials
Completed

NCT Number: NCT02573376

Antiviral Pharmacology and Adherence in Drug Users

Approximately one half of all Americans living with Hepatitis C virus (HCV) are drug users, yet they are the least likely to receive HCV treatment. Drug users are presumed non-adherent and therefore denied potentially life-saving therapy. This assumption can only be confirmed or dispelled through prospective pharmacologic and adherence studies in this population. Such studies would be greatly enhanced by an objective, quantitative measure of adherence which does not currently exist in the HCV field. Through the work proposed in this application, sixty HIV/HCV co-infected drug users will be treated with direct acting antiviral agents (DAA) and randomized to receive directly observed DAA therapy (DOT) vs. no directly observed therapy (no-DOT). Patients randomized to no-DOT will have wirelessly observed therapy (WOT) which involves use of a portable medication dispenser that sends a signal to a server with the date and time when the dispenser is opened. In Aim 1, DAA concentrations will be compared in those randomized to DOT vs. no-DOT. DAA pharmacokinetics will also be defined accounting for clinical factors like degree of hepatic impairment and use of concomitant recreational and antiretroviral drugs. The goal is to quantify adherence in this population and the effect of variable adherence on drug concentrations. In Aim 2, DAA concentrations (plasma, cellular, hair) will be linked with adherence patterns identified using WOT and DOT. The goal is to identify a drug concentration biomarker that predicts adherence in this population. In Aim 3, the relationship between DAA adherence (as measured by WOT and DOT and drug concentrations) and rate of cure will be established. The goal is to define the degree of adherence needed for HCV cure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Acquired Immunodeficiency Syndrome Blood-Borne Infections Chemically-Induced Disorders Communicable Diseases Digestive System Diseases Flaviviridae Infections Genital Diseases HIV Infections Hepatitis Hepatitis, Viral, Human Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Liver Diseases Mental Disorders RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Substance-Related Disorders Urogenital Diseases Virus Diseases Virus, Human Immunodeficiency

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to give informed consent
  • HIV-infected men and women
  • Chronic HCV infection as documented by quantifiable HCV RNA
  • HCV genotype 1, 4, 5, 6
  • 18-70 years of age
  • Willingness and ability to comply with study procedures, including DOT, WOT, and biweekly clinic visits
  • Considered an active drug user by HCV provider and self-reported drug use within the past month

Exclusion criteria

  • Glomerular filtration rate < 30 mL/min/1.73 m2
  • Receipt of prior HCV treatment and radiographic, histologic, or clinical evidence of cirrhosis
  • Decompensated liver disease (i.e., ascites, history of esophageal variceal bleeding, hepatic encephalopathy)
  • Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone)
  • Any medical condition that in the opinion of the investigators will make it challenging to adhere to the study protocol, such as unstable heart disease or cancer
  • Chronic Hepatitis B virus Infection
  • For females, active pregnancy or any intent to become pregnant
  • For both sexes, an unwillingness to use contraception during the study period
  • On parole or impending sentencing

Treatment and study plan

Directly Observed Therapy

Behavioral

Other names: DOT

Wirelessly Observed Therapy

Behavioral

Other names: WOT

Primary outcomes

  1. Compare each individual's modeled estimate of ledipasvir and metabolites of sofosbuvir (GS-331007 and GS-331007-TP) steady state concentrations (Css) from non-linear mixed effects modeling to Css in subjects receiving DOT vs. WOT.

    Time frame: 12 weeks

  2. Quantify GS-331007-TP concentrations in dried blood spots as a function of adherence (doses taken/doses prescribed).

    Time frame: 12 weeks

  3. Estimate the probability of HCV cure as a function of adherence using logistic regression.

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Collaborators

  • Denver Health and Hospital Authority
  • Gilead Sciences
  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2015
Primary completion
2020
Study completion
2021
First posted
Oct 9, 2015
Registry last updated
Mar 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.